We hypothesize that the possible reason is that ovarian cancer cells with high LOXL3 expression can enhance the interaction between the ECM and cells (e.g., through the activation of integrin signaling), thereby improving the resistance to chemotherapy-induced apoptosis and thus showing an enhanced survival advantage. Here, LOXL3 is linked to ovarian carcinoma.